Consensus guidelines for improving patients' understanding of invasive fungal disease and related risk prevention in the haematology/oncology setting, 2021

Patients with invasive fungal disease (IFD) are at significant risk of morbidity and mortality. A productive partnership between patients, their carers/families, and the multidisciplinary team managing the infection and any underlying conditions, is essential. Sharing information and addressing know...

Full description

Saved in:
Bibliographic Details
Published inInternal medicine journal Vol. 51; no. S7; pp. 220 - 233
Main Authors Fernando, Shevon S., Paige, Emma K., Dendle, Claire, Weinkove, Robert, Kong, David C. M., Omond, Paul, Routledge, David J., Szer, Jeff, Blyth, Christopher C.
Format Journal Article
LanguageEnglish
Published Melbourne John Wiley & Sons Australia, Ltd 01.11.2021
Wiley Subscription Services, Inc
Subjects
Antifungal agents
Antifungal Agents - therapeutic use
Australia - epidemiology
avoiding drug toxicity
Fungal diseases
Hematology
Humans
Infections
invasive fungal disease
Medical Oncology
Morbidity
Mycoses - prevention & control
Oncology
optimising antifungal therapy
patient information
Risk Factors
risk prevention
Australia
invasive fungal disease
patient information
avoiding drug toxicity
optimising antifungal therapy
risk prevention
Online AccessGet full text

Cover

More Information
Summary:Patients with invasive fungal disease (IFD) are at significant risk of morbidity and mortality. A productive partnership between patients, their carers/families, and the multidisciplinary team managing the infection and any underlying conditions, is essential. Sharing information and addressing knowledge gaps are required to ensure those at risk of IFD avoid infection, while those with suspected or confirmed infection optimise their therapy and avoid toxicities. This new addition to the Australian and New Zealand consensus guidelines for the management of IFD and antifungal use in the haematology/oncology setting outlines the key information needs of patients and their carers/families. It specifically addresses risk factor reduction, antifungal agents and adherence, and the risks and benefits of complementary and alternative therapies. Knowledge gaps are also identified to help inform the future research agenda.
Bibliography:Conflict of interest: The following working group members are consultants or advisory committee members or receive honoraria, fees for service, or travel assistance from; or have research or other associations with the organisations listed: C.D. – Amgen; D.K. – F2G, Merck Sharpe & Dohme, Australian Society for Antimicrobials, Australian Commission on Safety and Quality in Healthcare (ACSQHC) Antimicrobial Stewardship (AMS) Advisory Committee; D.J.R. – Sandoz, Celgene, Janssen, Amgen; J.S. – Alexion, Takeda, Pfizer, Novartis, Sanofi; R.W. – AbbVie, Janssen, Beigene.
Funding: C. C. Blyth is supported by a NHMRC Emerging Leadership Fellowship (1173163).
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1444-0903
1445-5994
DOI:10.1111/imj.15593